Why Prostate MRI Comes Before Biopsy (2026 Guide)

Prostate MRI is a test performed before biopsy to locate suspicious areas in advance, allowing doctors to precisely target that exact spot when taking tissue samples. If PSA levels are elevated or a digital rectal exam reveals an abnormality, a prostate MRI is done first; if a suspicious area is identified, it leads to an MRI fusion biopsy targeting that specific site.

Key Takeaways

• If your PSA level is elevated or a digital rectal exam finds an abnormality, a prostate MRI is done first, before biopsy.
• When the MRI shows a suspicious area, biopsy needles are aimed directly at that spot — this approach is called MRI fusion biopsy.
• The Gleason score and grade group obtained from the biopsy indicate how aggressive the cancer is, and they form the core basis for deciding the treatment direction afterward.
• Staging also relies on MRI to check whether the cancer is confined within the prostate, has broken through the capsule, or has invaded nearby organs.
• Before coming to Korea, having PSA results, MRI images, and biopsy results (Gleason score) ready is the key to a proper remote review (pre-arrival review).

What role does prostate MRI play?

• Prostate MRI is an imaging test used to identify the location and extent of areas within the prostate suspected of containing cancer. It is typically the first test performed when PSA blood levels are elevated or when a digital rectal exam reveals an abnormal finding.
• By identifying the suspicious area on MRI first, doctors can aim precisely at that spot to take tissue samples, rather than sampling the entire prostate at random. This approach — using MRI images to target the suspicious area during biopsy — is called MRI fusion biopsy.
• MRI is also used in staging, showing whether the cancer remains confined within the prostate, has broken through the prostate capsule, or has invaded the seminal vesicles or nearby organs.

What does the biopsy reveal?

• The biopsy result yields a Gleason score. This score reflects how different the cancer cells look from normal tissue, scored using two patterns that are added together, and the result is organized into grade groups ranging from 1 to 5. A higher grade group indicates a more aggressive cancer.
• PSA level, Gleason score (grade group), and the stage determined by MRI are combined to classify the case as low-risk, intermediate-risk, or high-risk. This risk group then determines the treatment direction — active surveillance, surgery, radiation therapy, and so on.

How does the testing sequence proceed?

• Step 1: PSA blood test and digital rectal exam are performed to check for abnormalities.
• Step 2: Prostate MRI is done to identify the location and extent of any suspicious area.
• Step 3: If a suspicious area is found on MRI, a biopsy targeting that spot (MRI fusion biopsy) is performed.
• Step 4: The Gleason score and grade group are determined from the biopsy results, and the PSA, MRI, and biopsy findings are combined to establish the risk group and treatment direction.

FAQ — Can MRI scans taken in my home country be used as they are?

Prostate MRI can be used as reference material if the original DICOM files and the written opinion (radiology report) are available. Recommended records for international patients to prepare include the full history of PSA measurement dates and values, prostate MRI, and biopsy/pathology reports (including Gleason score and grade group). If slides or paraffin blocks are available, re-review is also possible.

FAQ — If no suspicious area is found on MRI, can biopsy be skipped?

Prostate cancer often progresses slowly, so watchful monitoring without immediate treatment is included as a standard option for this cancer. However, whether and to what extent a biopsy should be performed is a decision made by the medical team based on a combination of PSA level, MRI findings, age, and coexisting conditions — this article alone cannot determine whether testing is necessary for any individual.

Sources and Notes

• This article was written based on the Prostate Cancer Note (National Cancer Information Center, National Cancer Center Korea, NCCN patient guidelines, and National Cancer Registration Statistics 2019–2023).
• This content is intended to provide general medical information, and actual diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Accurate diagnosis and treatment should always be determined through consultation with a medical professional.